ERBB2 and cancer: Increased infiltration of CD8+ T cells in the tumor is associated with improved clinical responses in several malignancies, including Her2-expressing cancers [70], while the presence of PMN-MDSC in the tumor is associated with its pro-tumorigenic immunosuppressive phenotype [68].